Form 4: C4 Therapeutics Chief Legal Officer Reports Stock Transactions

Jolie Siegel, Chief Legal Officer of C4 Therapeutics, reports acquisition and disposal of common stock and stock options.

Summary

• On February 13, 2025, Jolie Siegel, the Chief Legal Officer of C4 Therapeutics, had 2,135 shares of common stock withheld to cover tax obligations at a price of $3.2 per share, resulting in a holding of 54,353 shares.
• On February 14, 2025, Ms. Siegel acquired 56,500 shares of common stock in the form of Restricted Stock Units (RSUs) at $0, bringing the total holdings to 110,853 shares.
• Also on February 14, 2025, 2,914 shares were withheld for taxes at $3.18 per share, resulting in a final holding of 107,939 shares.
• Additionally, Ms. Siegel acquired options to purchase 84,700 shares of common stock at an exercise price of $3.18, exercisable starting March 14, 2025, and expiring on February 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock transactions by an officer. The acquisition of RSUs could be seen as slightly positive, but overall, it's a routine disclosure.

Positives

• The acquisition of 56,500 RSUs by the Chief Legal Officer could be seen as a positive sign of confidence in the company's future performance.

Future Outlook

The RSUs vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. The shares underlying the options vest in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment about the company's prospects.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance and are regularly disclosed by executives at publicly traded companies like C4 Therapeutics.
• Similar filings can be observed for executives at comparable biotech firms such as Arvinas, Inc. and Relay Therapeutics, Inc., reflecting standard practices in equity compensation and reporting.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock if the options are exercised and the RSUs vest.

Key Dates

Keywords

C4 Therapeutics, CCCC, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Chief Legal Officer, Jolie Siegel, Beneficial Ownership